Apply to trial NCT07346157

A few quick questions so the study team can decide if you might be a fit.

RecruitingDrug trial

Liothyronine in Combination With BIT Regimen for Medulloblastoma With or Without Minimal Residual Disease

This is a Phase 1/Phase 2 study assessing liothyronine (L-T3) immunotherapy and in combination with standard chemotherapy (bevacizumab, irinotecan and temozolomide (BIT)) in children and young adults with medulloblastoma that is relapsed or progressive after standard upfront therapy.

How this works

Answer a few questions
About 5 to 10 minutes. Skip-friendly where possible.
We connect you with the study team
When a site picks up your application, we introduce you to their team directly — with you on the thread.
The team reaches out to schedule screening
Usually within a few business days, via the contact you give.

EmailWe save your progress under this email and copy you when we connect you with the study team.

I agree that Hipa.ai may share my application — my name, contact details, and my answers, including health information — with the official study team for this trial so they can review my responses and contact me.

By continuing, you agree to our terms of service.

Liothyronine in Combination With BIT Regimen for Medulloblastoma With or Without Minimal Residual Disease

How this works

Answer a few questions

We connect you with the study team

The team reaches out to schedule screening